Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2014; 2(12): 893-898
Published online Dec 16, 2014. doi: 10.12998/wjcc.v2.i12.893
Published online Dec 16, 2014. doi: 10.12998/wjcc.v2.i12.893
Tranexamic acid for the management of uterine fibroid tumors: A systematic review of the current evidence
Panagiotis Peitsidis, Department of Obstetrics and Gynecology, Southend University Hospital, Essex SS0 0RY, United Kingdom
Panagiotis Peitsidis, Department of Obstetrics and Gynecology, Iaso Maternity Hospital, 17123 Athens, Greece
Anna Koukoulomati, Department of Obstetrics and Gynecology, Didymoteichon General Hospital, 68300 Didymoteicho, Greece
Author contributions: All authors generated the ideas and contributed to the writing of this paper.
Correspondence to: Dr. Panagiotis Peitsidis, Department of Obstetrics and Gynecology, Iaso Maternity Hospital, Proussis 22, 17123 Athens, Greece. panagiotis_pp@yahoo.com
Telephone: +30-21-07473793 Fax: +30-21-07473793
Received: March 26, 2014
Revised: October 28, 2014
Accepted: October 31, 2014
Published online: December 16, 2014
Revised: October 28, 2014
Accepted: October 31, 2014
Published online: December 16, 2014
Core Tip
Core tip: Uterine fibroid tumors are the most common gynecologic causes for menorrhagia. Tranexamic acid is a safe non-hormonal medication that significantly reduces abnormal menstrual bleeding. We conducted a systematic review of the contemporary evidence on the administration and efficacy of tranexamic acid in patients with menorrhagia associated with fibroid tumors of the uterus. Antifibrinolytic treatment may reduce blood loss perioperatively in myomectomies, and reduce menorrhagia in patients with fibroids. More double randomized studies with larger numbers of participants are necessary to reach more precise and safe conclusions.